{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:24:48Z","timestamp":1785324288014,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.purol.2019.11.007","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T16:56:09Z","timestamp":1579020969000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study"],"prefix":"10.1016","volume":"30","author":[{"given":"W.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Zugail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuziller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.purol.2019.11.007_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canep.2012.10.010","article-title":"Cancer incidence estimation at a district level without a national registry: a validation study for 24 cancer sites using French health insurance and registry data","author":"Uhry","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"32","key":"10.1016\/j.purol.2019.11.007_bib0065","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.urolonc.2014.05.008","article-title":"Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis","author":"Kim","year":"2014","journal-title":"Urol Oncol"},{"issue":"49","key":"10.1016\/j.purol.2019.11.007_bib0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer uing EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.purol.2019.11.007_bib0075","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.purol.2012.04.019","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"issue":"22","key":"10.1016\/j.purol.2019.11.007_bib0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie (CCAFU) pour la bonne pratique des instillations endov\u00e9sicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n\u2019envahissant pas le muscle (TVNIM)","author":"Roupret","year":"2012","journal-title":"Prog Urol"},{"issue":"12S","key":"10.1016\/j.purol.2019.11.007_bib0085","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l\u2019AFU\u00a0\u2013\u00a0Actualisation 2018\u00a0\u2013\u00a02020: tumeurs de la vessie French ccAFU guidelines\u00a0\u2013\u00a0Update 2018\u00a0\u2013\u00a02020: bladder cancer","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Prog Urol"},{"issue":"63","key":"10.1016\/j.purol.2019.11.007_bib0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate\u2013 and high-risk Ta T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"135","key":"10.1016\/j.purol.2019.11.007_bib0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-5347(17)45606-0","article-title":"Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer","author":"Lamm","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2019.11.007_bib0100","series-title":"Encyclop\u00e9die M\u00e9dico-Chirurgicale 18-244-A-21","article-title":"Mode d\u2019action et principes d\u2019utilisation des instillations endov\u00e9sicales","author":"Pettenati","year":"2015"},{"issue":"110","key":"10.1016\/j.purol.2019.11.007_bib0105","first-page":"e658","article-title":"Outpatient urological procedures in antibiotic-na\u00efve patients with bladder cancer with asymptomatic bacteriuria","author":"Herr","year":"2012","journal-title":"BJU Int"},{"issue":"109","key":"10.1016\/j.purol.2019.11.007_bib0110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/j.1464-410X.2011.10735.x","article-title":"Screening urine analysis before bacille Calmette-Gu\u00e9rin instillation does not reduce the rate of infectious complications","author":"Zhao","year":"2012","journal-title":"BJU Int"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:32:39Z","timestamp":1761114759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708719306426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1166708719306426"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.007","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}